Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes

What Was Tested

This randomized controlled trial paper looks at Semaglutide.

The effect of the interaction of semaglutide and physical training on pancreatic β-cell secretory function is unknown in patients with type 2 diabetes.

Why It Was Studied

Prior to this study, it is known that type 2 diabetes is linked to obesity and a sedentary lifestyle, leading to inadequate β-cell function and insulin resistance.

Limited research has explored the metabolic effects of combining exercise training with antidiabetic medications, particularly focusing on insulin secretion in patients with type 2 diabetes and moderately preserved β-cell function.

Who Took Part

Thirty-one patients with type 2 diabetes underwent 12 weeks of aerobic training alone or concurrent to treatment with semaglutide.

Patients randomly allocated to concurrent semaglutide and training were treated with semaglutide for 20 weeks before the training and evaluated at inclusion and again before and after the training intervention.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

A time span of 20 weeks appears in the methods.

Patients randomized to training were evaluated before and after training.

The primary outcome was a change in insulin secretory capacity with training, evaluated by a 2-stepped hyperglycemic (20 and 30 mM) clamp.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptides, Insulin and Semaglutide.

The authors tagged it with the keywords exercise, glucagon-like peptide 1 and insulin secretion.

What This Means in Plain Language

The paper is a randomized study of Semaglutide over 20 weeks.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Semaglutide compound page, all human trials.